Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | KDM5A | P29375 | 3/20 | 0.38 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.38 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | CEL | P19835 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7350448 | 1.00 | SIGMAR1 (0.50) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL1335898 | 1.00 | SIGMAR1 (0.50) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL7458663 | 0.98 | SIGMAR1 (0.54) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL7457536 | 0.98 | SIGMAR1 (0.54) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL2178634 | 0.98 | SIGMAR1 (0.54) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL7457427 | 0.98 | SIGMAR1 (0.54) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL7452816 | 0.98 | SIGMAR1 (0.54) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL98103 | 0.98 | SIGMAR1 (0.54) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL7458143 | 0.98 | SIGMAR1 (0.54) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL7348009 | 0.98 | SIGMAR1 (0.54) | SIGMAR1CYP1A2EPHX1KDM5APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2043644-A1 | NF- B INHIBITOR | Otsuka Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008010601-A1 | NF- ϰB INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | WO | disclosed |
| EP-1301480-B1 | 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LAB (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1474132-A1 | HISTAMINE-3 RECEPTOR LIGANDS FOR DIABETIC CONDITIONS | Abbott Laboratories (US) | 2004-11-10 | — | — | EP | disclosed |
| US-6620839-B2 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBOTT LABORATORIES | 2003-09-16 | — | — | US | disclosed |
| US-20030153548-A1 | Histamine-3 receptor ligands for diabetic conditions | ABBOTT LABORATORIES | 2003-08-14 | — | — | US | disclosed |
| WO-2003059342-A1 | HISTAMINE-3 RECEPTOR LIGANDS FOR DIABETIC CONDITIONS | ABBOTT LABORATORIES (US) | 2003-07-24 | — | — | WO | disclosed |
| US-20030134835-A1 | Histamine-3 receptor ligands for diabetes conditions | ABBOTT LABORATORIES | 2003-07-17 | — | — | US | disclosed |
| EP-1301480-A1 | 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2003-04-16 | — | — | EP | disclosed |
| US-6515013-B2 | For diseases or conditions caused by or exacerbated by histamine-3 receptor activity | ABBOTT LABORATORIES | 2003-02-04 | — | — | US | disclosed |
| US-20020137931-A1 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-09-26 | — | — | US | disclosed |
| US-20020035103-A1 | 1,3-Disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-03-21 | — | — | US | disclosed |
| WO-2002006223-A1 | 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137931-A1 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | SIGMAR1 227/4885CYP1A2 1588/4885EPHX1 592/4885 |
| US-20020035103-A1 | 1,3-Disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | SIGMAR1 227/4885CYP1A2 1588/4885EPHX1 592/4885 |
| US-20090326008-A1 | NF-kappa B Inhibitor | NFKBIA, NFKB2, IKBKB | SIGMAR1 2794/4885CYP1A2 3062/4885EPHX1 4476/4885 |
| US-20070179173-A1 | Carbostyril compound | GTF2F1, F3, GTF2F2 | SIGMAR1 2364/4885CYP1A2 1412/4885EPHX1 4541/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | SIGMAR1 2364/4885CYP1A2 1412/4885EPHX1 4541/4885 |
| US-20030153548-A1 | Histamine-3 receptor ligands for diabetic conditions | HRH4, HRH2, HRH3 | SIGMAR1 521/4885CYP1A2 1882/4885EPHX1 601/4885 |
| US-20030134835-A1 | Histamine-3 receptor ligands for diabetes conditions | HRH4, HRH2, HRH3 | SIGMAR1 644/4885CYP1A2 1680/4885EPHX1 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.